Lyell Wealth Management LP Acquires 2,906 Shares of SPDR S&P Biotech ETF (XBI)

Lyell Wealth Management LP grew its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 23.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,095 shares of the exchange traded fund’s stock after purchasing an additional 2,906 shares during the period. Lyell Wealth Management LP’s holdings in SPDR S&P Biotech ETF were worth $1,447,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Nvwm LLC increased its stake in shares of SPDR S&P Biotech ETF by 2.5% during the second quarter. Nvwm LLC now owns 21,631 shares of the exchange traded fund’s stock worth $2,059,000 after buying an additional 526 shares during the period. WealthPLAN Partners LLC increased its stake in shares of SPDR S&P Biotech ETF by 4.9% during the second quarter. WealthPLAN Partners LLC now owns 12,049 shares of the exchange traded fund’s stock worth $1,147,000 after buying an additional 560 shares during the period. BB&T Securities LLC increased its stake in shares of SPDR S&P Biotech ETF by 5.8% during the second quarter. BB&T Securities LLC now owns 11,533 shares of the exchange traded fund’s stock worth $1,097,000 after buying an additional 635 shares during the period. Cypress Capital Management LLC WY increased its stake in shares of SPDR S&P Biotech ETF by 51.8% during the second quarter. Cypress Capital Management LLC WY now owns 2,065 shares of the exchange traded fund’s stock worth $197,000 after buying an additional 705 shares during the period. Finally, Boothe Investment Group Inc. increased its stake in shares of SPDR S&P Biotech ETF by 2.5% during the third quarter. Boothe Investment Group Inc. now owns 29,111 shares of the exchange traded fund’s stock worth $2,791,000 after buying an additional 708 shares during the period.

XBI stock opened at $80.23 on Wednesday. SPDR S&P Biotech ETF has a fifty-two week low of $76.37 and a fifty-two week high of $101.55.



SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply